Corona puts a spanner in the works for large IO Biotech lung trial

The coronavirus outbreak will have consequences for IO Biotech. The development of the company's potential lung cancer drug, which is currently being tested in combination with MSD's blockbuster Keytruda, has been delayed. "We are doing everything we can to minimize the delay," says the CEO.

Photo: Gilead Sciences/Reuters/Ritzau Scanpix

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles